Sunitinib malate in solitary fibrous tumor (SFT)

Stacchiotti, Silvia; Negri, Tiziana; Libertini, Michela; Palassini, Elena; Marrari, Andrea; Troia, Beatrice De; Gronchi, Alessandro; Tos, Angelo Paolo Dei; Morosi, Carlo; Messina, A.; Pilotti, Silvana; Casali, Paolo G.

doi:10.1093/annonc/mds143

Cited by 150 publications

(95 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results seem to suggest a lower level of activity of pazopanib in SFT compared to sunitinib and bevacizumab plus temozolomide [5,6]. Median PFS of patients treated with pazopanib was 3 months, while a retrospective study on sunitinib in 31 SFT patients showed a Choi RR of about 50% with a 6-month median PFS [5]. Again, a Choi RR of 79% with a median PFS of 9.7 months was reported in SFT patients treated with bevacizumab and temozolomide [6].…”

Section: Discussionmentioning

confidence: 46%

“…Of note, the patient with a Choi response had the best PFS (15 months). Our results seem to suggest a lower level of activity of pazopanib in SFT compared to sunitinib and bevacizumab plus temozolomide [5,6]. Median PFS of patients treated with pazopanib was 3 months, while a retrospective study on sunitinib in 31 SFT patients showed a Choi RR of about 50% with a 6-month median PFS [5].…”

Section: Discussionmentioning

confidence: 55%

“…No RECIST responses could be observed but in one patient the effect of pazopanib was marked by a minor (<30%) decrease in tumour size and by a decrease in tumour density, thus classifying for a PR by Choi criteria [11]. As already described for SFT treated with bevacizumab, sunitinib and sorafenib, Choi criteria [4][5][6][7][8][9], originally conceived for GIST receiving imatinib [11], differed from RECIST in assessing response to therapy. Of note, the patient with a Choi response had the best PFS (15 months).…”

Section: Discussionmentioning

confidence: 97%

“…Very few data are available on the activity of pazopanib in solitary fibrous tumour (SFT), a rare STS subtype [3], the sensitivity of which to antiangiogenics like sorafenib, sunitinib and bevacizumab is reported [4][5][6][7][8][9]. Antiangiogenics were shown to produce durable disease stabilisation in a proportion of patients by means of tumour responses that were mostly non-dimensional [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…Antiangiogenics were shown to produce durable disease stabilisation in a proportion of patients by means of tumour responses that were mostly non-dimensional [5,6]. We already reported on the activity of pazopanib in a human high-grade dedifferentiated-SFT xenotransplanted into severe combined immunodeficiency (SCID) mice [10].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

Stacchiotti

Tortoreto

Baldi

et al. 2014

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Background: To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods: In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm 3 . Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure.

show abstract